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Background: Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of
Graves’ disease (GD). Diabetes mellitus (DM) has been reported to be a risk factor in
patients with GO. Moreover, GO can be more frequent and severe in type 2 diabetes
patients. High doses of intravenous glucocorticoids represent the first line treatment of
moderate-to-severe and active GO according to the international guidelines. However,
this therapy is contraindicated in uncontrolled diabetes and in patients with increased
cardiovascular risk. Some anti-diabetic drugs can exacerbate GO. We reported the
clinical case of an active and moderate-to-severe GO in a patient with uncontrolled type
2 DM and vascular complications.
Case Report: A 61-years-old patient came to our ambulatory for a recurrence of
GD and a moderate-to-severe bilateral GO. The patient had uncontrolled type 2 DM
during insulin therapy and a history of micro and macrovascular complications. At the
physical examination, the clinical activity score was 5 and the severity of GO was
moderate-to-severe. A blood sample showed overt hyperthyroidism and the persistence
of anti-TSH receptor antibodies (TRAb) during treatment with methimazole. A computed
tomography scan showed a moderate-to-severe bilateral exophthalmos. We discuss the
benefit/risk of treatment of GO in our patient.
Conclusion: The available guidelines do not focus on the treatment of diabetic patients
with uncontrolled diabetes and severe vascular complications, therefore our patient
represents a difficult therapeutic challenge. The screening of thyroid function and the
evaluation of GO could be useful in diabetic patients with autoimmune thyroid disease to
perform a correct treatment of these disorders.
Keywords: hyperthyroidism, diabetes mellitus, Graves’ orbitopathy, glucocorticoids, methotrexate, tocilizumab,
radiotherapy
INTRODUCTION
Graves’ orbitopathy (GO) is an autoimmune disorder and represents the main extrathyroidal
manifestation of Graves’ disease (GD). It can also occur in patients with euthyroid or hypothyroid
autoimmune thyroid disorders. The anatomical and histological findings of GO consist in soft
tissues enlargement of the orbits due to an inflammatory infiltration (including T-cells, B-cells,
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and mast cells) of retro-orbital adipose tissue and extra-ocular
muscles and proliferation of the connective tissue (1, 2).
The most common clinical features of GO are periorbital
edema, conjunctival chemosis, exophthalmos, diplopia, corneal
ulcerations, and upper-eyelid retraction; optic nerve compression
can occur in severe cases (1–3).
There are standardized criteria for assessing the activity (active
or inactive) and severity (mild, moderate-to-severe, and very
severe) of GO to address its management (1, 3).
Smoking and thyroid dysfunction are well-recognized risk
factors for GO, according to the guidelines of the European
Group on Graves’ Orbitopathy (EUGOGO) and the American
Thyroid Association (1, 3). Therefore, in all patients with
GD (also without GO) it is necessary to recommend not
smoking. The restoration of euthyroidism is essential to avoid the
exacerbation of GO (1, 3).
Diabetes mellitus (DM) has also been reported to be a risk
factor in patients with GO (4). The association of autoimmune
thyroid disease and type 1 diabetes mellitus is denominated as
autoimmune polyglandular syndrome type 3 variant or APS3 (5).
Moreover, GO can be more frequent and severe in type 2 diabetes
mellitus (T2DM) patients (6).
We reported the clinical case of an active and moderate-to-
severe GO in a patient with uncontrolled T2DM and vascular
complications. As the first line treatment for moderate-to-severe
and active GO, the EUGOGO guidelines recommend high doses
of intravenous glucocorticoids (methylprednisolone); however,
this therapy is contraindicated in uncontrolled diabetes and in
patients with associated important cardiovascular risk factors (1).
The guidelines do not focus on the treatment of diabetic
patients with severe vascular complications, therefore, the choice
of a possible therapy for this category of patients is a difficult task.
CASE PRESENTATION
A 61-years-old patient came to our ambulatory for a recurrence
of GD and a moderate-to-severe bilateral GO (Figure 1). He
referred that GO developed at the first manifestation of GD
in 2014 and worsened over time. The patient had type 2 DM
with a metabolic glycemic decompensation (HbA1c 8.5%) during
insulin therapy. He had been treated with thiazolidinediones
(TZDs) many years before.
The patient had a history of micro andmacrovascular diabetes
complications, diabetic nephropathy with microalbuminuria and
mild non-proliferative diabetic retinopathy. He mentioned that
he had undergone an aorto-coronary bypass for ischemic heart
disease and a foot amputation of the first metatarsal for diabetes.
At the physical examination, the thyroid was enlarged
and the assessment of the GO activity showed the swelling
of eyelids and caruncle and chemosis, confirming an active
GO (CAS≥3) according to the European Thyroid Association
guidelines. Severity of GO was moderate-to-severe for the
presence of exophthalmos ≥3mm above normal, diplopia, and
severe soft tissue involvement. A blood sample showed overt
hyperthyroidism and the persistence of thyrotropin receptor
antibodies (TRAb) during treatment with anti-thyroid drugs
FIGURE 1 | Clinical features of Graves’ orbitopathy in our patient.
TABLE 1 | Thyroid function at our first evaluation.
Reference range
TSH 0.01 µU/ML (0.41–4.30)
FT3 7.6 PG/ML (3.0–4.70)
FT4 23.1 pmol/l (9–20)
TRAB 26.8 U/L (<1.75)
ABTG 780 U/ML (0–60)
(Table 1). Thyroid ultrasound showed an increased thyroid
volume and vascularization. A computed tomography scan
showed a bilateral exophthalmos with a thickening of the ocular
extrinsic musculature.
We analyzed the literature data to choose the best treatments
of GO for our diabetic patient.
DISCUSSION
Type 1 diabetes mellitus (T1DM) is a risk factor for GD for
the associated common genetic susceptibility. Moreover, the
incidence of optic neuropathy (a very severe GO) is higher
in patients with GO and type 1 DM (33.3%), compared to
patients with GO without DM (3.9%). These data could be
explained by the low oxygenation of the optic nerve and his
compression by the expansion of extraocular muscles due to
microvascular complications of DM (4, 7). A strong link between
GD and type 1 DM, but not with type 2 DM was reported
in an Italian study (6). However, GO was more severe in
patients with long term T2DM and associated microvascular
and macrovascular complications. Insulin-like growth factor I
(IGF1) bioavailability was found to be increased in patients
with T2DM and GO because of the insulin-resistance; the
compensatory hyperinsulinemia probably reduced the IGF-1
binding proteins 1 and 2 (6). Furthermore, an overexpression
of IGF-1 receptor was found in orbital pre-adipocytes/fibroblast.
All these factors could contribute to the increase adipogenesis,
inflammation, and overproduction of hyaluronan in orbital
tissue (6).
Treatment of T2DM can affect the onset and progression of
GO. In fact, TZDs, which are potent agonists of peroxisome
proliferator activated receptor-γ (PPAR-γ), can exacerbate
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GO. PPAR-γ is located in the adipose tissue and can
increase retrobulbar fat and stimulate the TSH receptor
expression in orbital fibroblasts (6, 8). Therefore, TZDs
can contribute to the pathogenesis of GO in T2 diabetic
patients.
On the contrary, a recent in vitro study (carried out
on fibroblast cultures taken from GO patients undergoing
orbital decompression) demonstrated a possible therapeutic
effects of biguanides by inhibiting hyaluronan synthesis and
pro-inflammatory molecule production in orbital fibroblasts
(9). Moreover, metformin and phenformin significantly inhibit
the adipogenic pathway during the differentiation of orbital
fibroblasts (9).
The current guidelines do not recommend specific therapeutic
options for GO in patients with uncontrolled DM and vascular
complications, even in those with cardiovascular comorbidity
(1). Intravenous high-dose of glucocorticoids, alone or in
association with ciclosporin, are considered the treatment of
choice for moderate-to severe active GO for their efficacy (1).
However, these drugs are contraindicated in uncompensated
diabetes and in patients with severe hypertension and coronary
heart disease. Orbital radiotherapy, which is recommended
as a second-line treatment for GO can be used alone
or in combination with glucocorticoids (1). This treatment
improves diplopia and ocular motility and is considered
relatively safe. However, diabetic retinopathy and uncontrolled
hypertension represent an absolute contraindication for this
treatment because of the increased worsening of retinopathy
(1, 10, 11).
The off-label use of rituximab (RTX) is also considered a
second-line treatment by the EUGOGO guidelines (1). RTX
is a monoclonal antibody anti-CD20 commonly used in the
treatment of autoimmune disease and B cell lymphomas.
Two randomized clinical trials evaluated the efficacy of RTX
(12, 13) and showed conflicting results. RTX was effective
in patients with active moderate-to-severe GO compared
with intravenous glucocorticoids in the study by Salvi et
al. in which 32 patients with thyroid-associated orbitopathy
were treated with intraorbital low doses of RTX vs. high
doses of systemic glucocorticoids (12). These results highlight
the efficacy of RTX in reducing orbitopathy CAS and
severity. However, important side effects (such as myocardial
infarction and arrhythmias) have been reported in cardiac
patients (14). Moreover, some cases of optic neuropathy
have been described in patients with GO treated with RTX
(15).
There are some data on the potential use of methotrexate
(MTX), an immune suppressive drug that inhibits folic acid
synthesis and is used for the treatment of several autoimmune
diseases. MTX may have a potential role in GO for its
immunosuppressive properties (16). One study showed its
efficacy in the treatment of GO as a corticosteroid-sparing agent
in patients previously treated with prednisone (17).
A successful treatment with tocilizumab has been reported in
two patients with GO (18). Tocilizumab is a IgG monoclonal
antibody targeting the IL-6 receptor; it is used for the
treatment of rheumatoid arthritis not-responsive to conventional
anti-rheumatic drugs. As demonstrated by in vitro studies,
pro-inflammatory cytokine IL-6 and TSH receptors mutually
stimulate their expression in orbital fibroblasts of patients
with GO (19, 20). Tocilizumab interrupts the inflammatory
process by blocking the IL-6 receptors (20); this IL-6 signal
inhibition can have positive effects in diabetic subjects. TSH
and IGF-1 work interdependently in the GO pathogenesis,
and antibodies recognizing and activating the IGF-IR signaling
have been detected in patients with GD (21). Moreover, an
inverse correlation was found between IGF-IR and the CAS (22).
Teprotumumab, a IGF-1 receptor inhibitory antibody, has been
evaluated in a recent multicenter double-masked randomized
placebo-controlled trial in patients with GO. This treatment
improved proptosis and reduced the CAS (22). However,
hyperglycemia was observed in some patients with diabetes (22).
All of these options were not considered suitable for
our patient because of the potential side-effects. Moreover,
thyroidectomy was contraindicated for the severe cardiac
conditions.
Our patient had a mild non-proliferative diabetic
retinopathy. Therefore, we discussed with him about the
benefit/risk of treatment of GO and decided to perform
low-doses of intravenous glucocorticoids (1,500mg in 6-
weeks) administration (after monitoring glycemic and cardiac
conditions) only in the event of further exacerbation of his
ocular symptoms, eventually associated with fractionated
low-dose orbital radiotherapy (1Gy per week over a 20-weeks
period) (10, 23, 24). This scheme of 1Gy per week over a
20-weeks period was effective and better tolerated compared to
2Gy daily over 2-weeks in patients with moderately severe GO,
showing lower rates of side effects compared to high RX dose
(23).
CONCLUSIONS
Diabetes mellitus can be considered a risk factor for GO in
patient with Graves’ disease or autoimmune thyroid disorders.
Considering the high prevalence and severity of GO in patients
with T1 and T2DM, the screening of thyroid function and
the evaluation of orbitopathy is useful in diabetic patients to
perform a correct treatment of these disorders. Caution should
be placed for the choice of anti-diabetic drugs in patients with
GO and DM.
Based on the above mentioned considerations, our patient
represents a difficult therapeutic challenge. In the future,
international guidelines could help clarify the therapeutic options
for GO in patients with uncontrolled DM and associated vascular
complications.
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